Raily Aesthetic Medicine International Holdings Limited Provided consolidated unaudited earnings guidance for the year ended 31 December 2022. For the period, the Board expects the Group to record a revenue of approximately RMB 165 million (2021: revenue of approximately RMB 188 million) and expects to record a loss attributable to owners of the parent of approximately RMB 16 million (2021: loss of approximately RMB18 million).
Raily Aesthetic Medicine International Holdings Limited
Equities
2135
KYG7356A1215
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.152 HKD | +1.33% | +4.83% | -68.33% |
Apr. 19 | Raily Aesthetic Medicine International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Raily Aesthetic Medicine Forecasts Wider Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-68.33% | 10.85M | |
-18.52% | 16.6B | |
+5.41% | 12.87B | |
+3.98% | 11.78B | |
+4.38% | 10.28B | |
+28.07% | 8.6B | |
-4.98% | 7.64B | |
+6.76% | 6.82B | |
+6.08% | 6.4B | |
+48.17% | 4.58B |
- Stock Market
- Equities
- 2135 Stock
- News Raily Aesthetic Medicine International Holdings Limited
- Raily Aesthetic Medicine International Holdings Limited Provides Consolidated Unaudited Earnings Guidance for the Year Ended 31 December 2022